This disparity likely reflects the greater physiological complexity and variability inherent in Type 1 diabetes management, where autoimmune pancreatic destruction creates more unpredictable glucose-insulin dynamics compared to the metabolic dysfunction characteristic of Type 2 diabetes. This evidence concerns the gene INS and type 1 diabetes mellitus.